Brookstone Capital Management’s AstraZeneca AZN Stock Holding History

Brookstone Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$786K	Buy	4,146 +2,970	+253%	+$559K	0.01%	788
2026 Q1	$232K	Sell	1,176 -61	-5%	-$11.8K	﹤0.01%	1118
2025 Q4	$227K	Buy	+1,237	New	+$217K	﹤0.01%	1075
2024 Q2	–	Sell	-2,322	Closed	-$315K	–	952
2024 Q1	$315K	Buy	+2,322	New	+$307K	0.01%	750
2022 Q3	–	Sell	-16,682	Closed	-$2.23M	–	783
2022 Q2	$2.23M	Buy	16,682 +13,681	+456%	+$1.8M	0.05%	271
2022 Q1	$424K	Buy	3,001 +1,184	+65%	+$142K	0.01%	587
2021 Q4	$209K	Sell	1,817 -9	-0.5%	-$1.06K	﹤0.01%	707
2021 Q3	$221K	Sell	1,826 -1,001	-35%	-$117K	﹤0.01%	678
2021 Q2	$343K	Buy	+2,827	New	+$310K	0.01%	555
2015 Q4	–	Sell	-50	Closed	-$3K	–	217
2015 Q3	$3K	Buy	+50	New	+$3.29K	﹤0.01%	1600

Other funds holding AZN

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return

ZIC

ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return

AIM

Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return

CAM

Cidel Asset Management Toronto, Ontario, Ontario, Canada $2.08B AUM 24.89% 1-Year Est. Return

SAM

Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return

PAS

Professional Advisory Services Vero Beach, Florida $836M AUM 25.79% 1-Year Est. Return

Brookstone Capital Management's AZN Position: Q2 2026 in Review

Brookstone Capital Management increased its AstraZeneca (AZN) stake by 253% in Q2 2026, buying an estimated $559K and bringing the position to 4,146 shares worth $786K. The position accounts for 0.01% of the portfolio, ranked #788.

Brookstone Capital Management first reported a position in AZN in Q3 2015 and has held it in 10 quarters since. The position peaked at $2.23M in Q2 2022. 240 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Brookstone Capital Management held 4,146 shares of AstraZeneca worth $786K as of Q2 2026.
Brookstone Capital Management bought 2,970 AstraZeneca shares in Q2 2026, an estimated $559K.
AstraZeneca made up 0.01% of Brookstone Capital Management's portfolio in Q2 2026, its #788 holding.
Brookstone Capital Management first reported a position in AstraZeneca in Q3 2015 and has held it in 10 quarters since.
Brookstone Capital Management's AstraZeneca position peaked at $2.23M in Q2 2022.
240 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Brookstone Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.